Loading
A phase 3 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Amgen, active and no longer recruiting.
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) is a phase 3 interventional study registered as NCT06430866 by Amgen, with 163 participants enrolled, started 2024-09-12 and due to reach its primary completion in 2026-12-14. Interventions recorded: ABP 234, Pembrolizumab. Conditions listed: Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Amgen, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Amgen, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/